drugset / Trial / NCT04536961

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

NCT04536961

Phase 1 Completed 56 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.

Timeline

Start
2020-09-10
Primary completion
2020-12-25
Completion
2020-12-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule Oral
Background Famotidine Other / unclassified

Indications

No indication recorded.